We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Infection by Cold Virus Triggers Major Changes in Nasal Gene Activity

By LabMedica International staff writers
Posted on 03 Nov 2008
A team of molecular virologists from two universities and a major pharmaceutical company has identified the genes whose activities are transformed by infection with Rhinovirus, the most common cold virus.

Investigators from the University of Calgary (Alberta, Canada) infected a group of volunteers with a Rhinovirus serotype purified at the University of Virginia (Charlottesville, USA) in a nasal spray formulated at Procter & Gamble (Cincinnati, OH, USA). More...
A control group was treated with only the virus-free nasal spray. Symptom scores and viral titers in nasal epithelial scrapings were measured, and changes in gene expression – as ascertained with high-throughput micro array technology – were assessed eight and 48 hours after inoculation. Real time reverse transcription-polymerase chain reaction for the antiviral protein viperin (virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible) and rhinoviruses was used in naturally acquired infections, and viperin mRNA levels and viral titers were measured in cultured cells.

Results published in the online edition of the November 1, 2008, issue of the American Journal of Respiratory and Critical Care Medicine revealed that no changes in gene expression were observed eight hours after viral infection, but 11,887 gene transcripts were significantly altered in scrapings obtained two days after infection. Major groups of up-regulated genes included chemokines, signaling molecules, interferon-responsive genes, and antivirals. The epithelial cells of the test group were found to produce an average of 6.5 times more viperin gene product that did the cells taken from the control group.

"This study shows that after rhinovirus infection, cold symptoms develop because parts of our immune system are in overdrive,” said contributing author Dr. Lynn Jump, principal researcher at Procter & Gamble. "The findings are important because they provide us a blueprint for developing the ideal cold treatment: one that maintains the body's natural antiviral response while normalizing the inflammatory response.”

"Rhinovirus is the major cause of the common cold, but it is also an important pathogen in more serious conditions, such as asthma and chronic obstructive pulmonary disease (COPD),” said first author Dr. David Proud, professor, of physiology and biophysics at the University of Calgary. "The study's findings are a major step toward more targeted cold prevention and treatment strategies while also serving as a valuable roadmap for the broader respiratory science community.”

Related Links:
University of Calgary
University of Virginia
Procter & Gamble


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.